A New Era: Drug Development for Acute Myeloid Leukemia After the Approval of Venetoclax
Although the 7 + 3 regimen has been the standard of care for acute myeloid leukemia for decades, it may be time to reassess its value and utility.
Acute Myeloid Leukemia
High Incidence of Severe Respiratory Adverse Events Associated With Induction Therapy in Children, Adolescents With AML
A retrospective study evaluated the incidence of respiratory adverse events in children and adolescents with AML who received induction chemotherapy.
Many Older Patients With AML Not Receiving Active Treatment
No active treatment more likely with older age, lower household income, unmarried status, comorbidities.
Venetoclax Plus Hypomethylating Agents May Offer Treatment Backbone for High-Risk AML
Over half of patients with TP53-mutated acute myeloid leukemia who received the combination therapy experienced a response.
Sorafenib Plus Intensive Chemotherapy Improves Outcomes in FLT3-Mutated Acute Myeloid Leukemia
Median overall survival was 42 months in patients who received sorafenib and 13 months in patients who received chemotherapy alone.
Older Adults With AML Can Achieve Long-Term Survival After Intensive Chemotherapy, ICU Admission
Approximately 30% of older patients with AML who had or were receiving active treatment were admitted to the ICU. This study sought to determine overall survival for these patients.
Predicting Bleeding Risk in Acute Myeloid Leukemia With Thrombocytopenia With Platelet Function Tests
Platelet aggregation and platelet activation were both independently associated with bleeding risk.
Evaluating the Cost-Effectiveness of Acute Myeloid Leukemia Treatment
The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.
Heparin Derivative CX-01 May Boost Standard AML Induction
The new findings suggest that CX-01 may strengthen the efficacy of standard AML induction.
Study Found Gilteritinib Superior to Salvage Chemotherapy in FLT3-Mutated Refractory AML
The researchers examined 37 recurrently mutated genes in AML using next-generation sequencing.
Next post in ASCO 2019
